Skip to main content
Top
Published in: Diabetologia 5/2010

01-05-2010 | Article

Folic acid administration reduces neointimal thickening, augments neo-vasa vasorum formation and reduces oxidative stress in saphenous vein grafts from pigs used as a model of diabetes

Authors: J. Bloor, N. Shukla, F. C. T. Smith, G. D. Angelini, J. Y. Jeremy

Published in: Diabetologia | Issue 5/2010

Login to get access

Abstract

Aims/hypothesis

There is evidence that plasma homocysteine augments vein graft failure and that it augments both micro- and macro-angiopathy in patients with diabetes mellitus. It is therefore suggested that homocysteine may augment vein graft thickening, a major cause of vein graft failure, in diabetic patients, as well as impairing adaptive growth of a new vasa vasorum, possibly through overproduction of superoxide. In order to test these proposals, the effect of folic acid administration, which lowers plasma homocysteine, on vein graft thickening and microvessel density was studied in pigs used as a model of diabetes.

Methods

Non-ketotic hyperglycaemia was induced in Landrace pigs by intravenous injection of streptozotocin, and folic acid was fed daily for 1 month. Vein grafts were excised and the thickness of the neointima and media and microvessel density were assessed by planimetry and superoxide formation.

Results

Plasma total homocysteine was significantly reduced by folic acid in both control and diabetic pigs, whereas glucose was unchanged. Compared with controls, diabetic pigs showed increased neointimal thickness and superoxide formation and decreased adventitial microvessel density. Folic acid reduced neointimal thickness and superoxide formation and augmented microvessel density in diabetic but not in control pigs.

Conclusions

Folic acid administration reduces neointimal thickening, augments vasa vasorum neoformation and reduces oxidative stress in saphenous vein grafts from diabetic pigs. Folic acid may therefore be particularly effective in reducing vein graft failure in diabetic patients.
Literature
1.
go back to reference Mortwani JG, Topol EJ (1998) Aortocoronary saphenous vein graft disease. Pathogenesis, predisposition and prevention. Circulation 97:916–931 Mortwani JG, Topol EJ (1998) Aortocoronary saphenous vein graft disease. Pathogenesis, predisposition and prevention. Circulation 97:916–931
2.
go back to reference Varty K, Allen KE, Bell PRF, London NJM (1993) Infra-inguinal vein graft stenosis. Br J Surg 80:825–833CrossRefPubMed Varty K, Allen KE, Bell PRF, London NJM (1993) Infra-inguinal vein graft stenosis. Br J Surg 80:825–833CrossRefPubMed
3.
go back to reference Jeremy JY, Gadsdon P, Shukla N et al (2007) On the biology of saphenous vein grafts fitted with external synthetic sheaths and stents. Biomaterials 28:895–908CrossRefPubMed Jeremy JY, Gadsdon P, Shukla N et al (2007) On the biology of saphenous vein grafts fitted with external synthetic sheaths and stents. Biomaterials 28:895–908CrossRefPubMed
4.
go back to reference Jeremy JY, Mehta D, Bryan AJ, Lewis D, Angelini GD (1997) Platelets and saphenous vein graft failure following coronary artery bypass graft surgery. Platelets 8:295–309CrossRefPubMed Jeremy JY, Mehta D, Bryan AJ, Lewis D, Angelini GD (1997) Platelets and saphenous vein graft failure following coronary artery bypass graft surgery. Platelets 8:295–309CrossRefPubMed
5.
go back to reference Iwama Y, Mokuno H, Yokoi H (1998) Elevated levels of plasma homocysteine related to saphenous vein graft disease after coronary artery bypass graft surgery. J Cardiol 32:357–362PubMed Iwama Y, Mokuno H, Yokoi H (1998) Elevated levels of plasma homocysteine related to saphenous vein graft disease after coronary artery bypass graft surgery. J Cardiol 32:357–362PubMed
6.
go back to reference Irvine C, Wilson YG, Currie IC (1996) Hyperhomocysteinaemia is a risk factor for vein graft stenosis. Eur J Vasc Endovasc Surg 12:304–309CrossRefPubMed Irvine C, Wilson YG, Currie IC (1996) Hyperhomocysteinaemia is a risk factor for vein graft stenosis. Eur J Vasc Endovasc Surg 12:304–309CrossRefPubMed
7.
go back to reference Jeremy JY, Shukla N, Angelini GD et al (2002) Sustained increases in homocysteine, copper and ceruloplasmin following coronary artery bypass grafting. Ann Thorac Surg 74:1553–1557CrossRefPubMed Jeremy JY, Shukla N, Angelini GD et al (2002) Sustained increases in homocysteine, copper and ceruloplasmin following coronary artery bypass grafting. Ann Thorac Surg 74:1553–1557CrossRefPubMed
8.
go back to reference Shukla N, Thompson CS, Angelini GD et al (2002) Homocysteine augments the reduction of endothelium dependent relaxation and cGMP formation in diabetic rabbits. Diabetologia 45:1325–1331CrossRefPubMed Shukla N, Thompson CS, Angelini GD et al (2002) Homocysteine augments the reduction of endothelium dependent relaxation and cGMP formation in diabetic rabbits. Diabetologia 45:1325–1331CrossRefPubMed
9.
go back to reference Shukla N, Angelini GD, Jeremy JY (2007) Interactive effects of homocysteine and copper on angiogenesis in porcine isolated saphenous vein. Ann Thorac Surg 84:43–49CrossRefPubMed Shukla N, Angelini GD, Jeremy JY (2007) Interactive effects of homocysteine and copper on angiogenesis in porcine isolated saphenous vein. Ann Thorac Surg 84:43–49CrossRefPubMed
10.
go back to reference Jeremy JY, Yim AP, Wan S, Angelini GD (2002) Oxidative stress, nitric oxide and vascular disease. Cardiovasc Surg 17:324–327 Jeremy JY, Yim AP, Wan S, Angelini GD (2002) Oxidative stress, nitric oxide and vascular disease. Cardiovasc Surg 17:324–327
11.
go back to reference Jeremy JY, Rowe D, Emsley AM et al (1999) Nitric oxide and vascular smooth muscle cell proliferation. Cardiovasc Res 43:658–665CrossRefPubMed Jeremy JY, Rowe D, Emsley AM et al (1999) Nitric oxide and vascular smooth muscle cell proliferation. Cardiovasc Res 43:658–665CrossRefPubMed
12.
go back to reference Wald DS, Law MR, Morris JK (2002) Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325:1202CrossRefPubMed Wald DS, Law MR, Morris JK (2002) Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325:1202CrossRefPubMed
13.
go back to reference Schnyder G, Roffi M, Pin R et al (2001) Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 345:1593–1600CrossRefPubMed Schnyder G, Roffi M, Pin R et al (2001) Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 345:1593–1600CrossRefPubMed
14.
go back to reference Schnyder G, Roffi M, Pin R et al (2003) Effect of homocysteine-lowering therapy on restenosis after percutaneous coronary intervention for narrowings in small coronary arteries. Am J Cardiol 91:1265–1269CrossRefPubMed Schnyder G, Roffi M, Pin R et al (2003) Effect of homocysteine-lowering therapy on restenosis after percutaneous coronary intervention for narrowings in small coronary arteries. Am J Cardiol 91:1265–1269CrossRefPubMed
15.
go back to reference Shukla N, Hotston M, Persad N, Angelini GD, Jeremy JY (2009) The administration of folic acid improves erectile function and reduces intracavernosal oxidative stress in the diabetic rabbit. Br J Urol Int 103:98–103 Shukla N, Hotston M, Persad N, Angelini GD, Jeremy JY (2009) The administration of folic acid improves erectile function and reduces intracavernosal oxidative stress in the diabetic rabbit. Br J Urol Int 103:98–103
16.
go back to reference Shukla N, Greaves NS, Angelini GD, Jeremy JY (2008) Folic acid reduces intravascular oxidative stress in diabetic rabbits. Metabolism 57:774–781CrossRefPubMed Shukla N, Greaves NS, Angelini GD, Jeremy JY (2008) Folic acid reduces intravascular oxidative stress in diabetic rabbits. Metabolism 57:774–781CrossRefPubMed
17.
go back to reference Jensen-Waern M, Andersson M, Kruse R et al (2009) Effects of streptozotocin-induced diabetes in domestic pigs with focus on the amino acid metabolism. Lab Anim 43:249–254CrossRefPubMed Jensen-Waern M, Andersson M, Kruse R et al (2009) Effects of streptozotocin-induced diabetes in domestic pigs with focus on the amino acid metabolism. Lab Anim 43:249–254CrossRefPubMed
18.
go back to reference Thompson CS (2008) Animal models of diabetes mellitus: relevance to vascular complications. Curr Pharm Des 14:309–324CrossRefPubMed Thompson CS (2008) Animal models of diabetes mellitus: relevance to vascular complications. Curr Pharm Des 14:309–324CrossRefPubMed
19.
go back to reference Jeremy JY, Thomas AC (2010) Animal models for studying neointima formation. Curr Vasc Pharmacol (in press) Jeremy JY, Thomas AC (2010) Animal models for studying neointima formation. Curr Vasc Pharmacol (in press)
20.
go back to reference Koopmans SJ, Mroz Z, Dekker R et al (2006) Association of insulin resistance with hyperglycemia in streptozotocin-diabetic pigs: effects of metformin at isoenergetic feeding in a type 2-like diabetic pig model. Metabolism 55:960–971CrossRefPubMed Koopmans SJ, Mroz Z, Dekker R et al (2006) Association of insulin resistance with hyperglycemia in streptozotocin-diabetic pigs: effects of metformin at isoenergetic feeding in a type 2-like diabetic pig model. Metabolism 55:960–971CrossRefPubMed
21.
go back to reference Mehta D, George SJ, Jeremy JY et al (1984) External stenting reduces long-term medial and neointimal thickening and platelet derived growth factor expression in a pig model of arterio-venous bypass grafting. Nat Med 4:235–239CrossRef Mehta D, George SJ, Jeremy JY et al (1984) External stenting reduces long-term medial and neointimal thickening and platelet derived growth factor expression in a pig model of arterio-venous bypass grafting. Nat Med 4:235–239CrossRef
22.
go back to reference Wan S, Yim A, Bulbulia RA et al (2004) The endothelin 1A receptor antagonist BSF 302146 is a potent inhibitor of porcine vein graft thickening in vivo. J Thorac Cardiovasc Surg 127:1317–1322CrossRefPubMed Wan S, Yim A, Bulbulia RA et al (2004) The endothelin 1A receptor antagonist BSF 302146 is a potent inhibitor of porcine vein graft thickening in vivo. J Thorac Cardiovasc Surg 127:1317–1322CrossRefPubMed
23.
go back to reference Wan S, Shukla N, Angelini GD, Yim AP, Johnson JL, Jeremy JY (2007) Nitric oxide-donating aspirin (NCX 4016) inhibits neointimal thickening in a pig model of saphenous vein-carotid artery interposition grafting: a comparison with aspirin and morpholinosydnonimine (SIN-1). J Thorac Cardiovasc Surg 134:1033–1039CrossRefPubMed Wan S, Shukla N, Angelini GD, Yim AP, Johnson JL, Jeremy JY (2007) Nitric oxide-donating aspirin (NCX 4016) inhibits neointimal thickening in a pig model of saphenous vein-carotid artery interposition grafting: a comparison with aspirin and morpholinosydnonimine (SIN-1). J Thorac Cardiovasc Surg 134:1033–1039CrossRefPubMed
24.
go back to reference Vijayan V, Shukla N, Johnson JL et al (2004) Long-term reduction of medial and intimal thickening in porcine saphenous vein grafts with a polyglactin biodegradable external sheath. J Vasc Surg 40:1011–1019CrossRefPubMed Vijayan V, Shukla N, Johnson JL et al (2004) Long-term reduction of medial and intimal thickening in porcine saphenous vein grafts with a polyglactin biodegradable external sheath. J Vasc Surg 40:1011–1019CrossRefPubMed
25.
go back to reference Wan S, Arifi AA, Chan MCW et al (2006) Perivenous application of fibrin glue in porcine saphenous vein–carotid artery interposition grafts: impact on medial thickening. Eur J Cardiothorac Surg 29:742–746CrossRefPubMed Wan S, Arifi AA, Chan MCW et al (2006) Perivenous application of fibrin glue in porcine saphenous vein–carotid artery interposition grafts: impact on medial thickening. Eur J Cardiothorac Surg 29:742–746CrossRefPubMed
26.
go back to reference Muzaffar S, Jeremy JY, Angelini GD, Stuart Smith K, Shukla N (2003) The role of the endothelium and nitric oxide synthases in modulating superoxide formation induced by endotoxin and cytokines in porcine pulmonary arteries. Thorax 58:598–604CrossRefPubMed Muzaffar S, Jeremy JY, Angelini GD, Stuart Smith K, Shukla N (2003) The role of the endothelium and nitric oxide synthases in modulating superoxide formation induced by endotoxin and cytokines in porcine pulmonary arteries. Thorax 58:598–604CrossRefPubMed
27.
go back to reference Muzaffar S, Shukla N, Angelini GD, Jeremy JY (2005) Sildenafil citrate and sildenafil nitrate are potent inhibitors of superoxide formation and gp91phox expression in porcine pulmonary artery endothelial cells. Br J Pharmacol 146:109–117CrossRefPubMed Muzaffar S, Shukla N, Angelini GD, Jeremy JY (2005) Sildenafil citrate and sildenafil nitrate are potent inhibitors of superoxide formation and gp91phox expression in porcine pulmonary artery endothelial cells. Br J Pharmacol 146:109–117CrossRefPubMed
28.
go back to reference Muzaffar S, Shukla N, Lobo C, Angelini GD, Jeremy JY (2004) Iloprost inhibits NADPH oxidase expression and superoxide release in porcine pulmonary arteries and cells stimulated with thromboxane A2, isoprostane F2α and cytokines. Br J Pharmacol 141:488–496CrossRefPubMed Muzaffar S, Shukla N, Lobo C, Angelini GD, Jeremy JY (2004) Iloprost inhibits NADPH oxidase expression and superoxide release in porcine pulmonary arteries and cells stimulated with thromboxane A2, isoprostane F and cytokines. Br J Pharmacol 141:488–496CrossRefPubMed
29.
go back to reference Muzaffar S, Shukla N, Angelini GD, Jeremy JY (2005) Hypoxia simultaneously induces the expression of gp91phox and endothelial nitric oxide synthase which promotes peroxynitrite formation in the pulmonary artery. Thorax 60:305–313CrossRefPubMed Muzaffar S, Shukla N, Angelini GD, Jeremy JY (2005) Hypoxia simultaneously induces the expression of gp91phox and endothelial nitric oxide synthase which promotes peroxynitrite formation in the pulmonary artery. Thorax 60:305–313CrossRefPubMed
30.
go back to reference Shukla N, Maher J, Masters J, Angelini GD, Jeremy JY (2006) Does oxidative stress change ceruloplasmin from a protective to a vasculopathic risk factor? Atherosclerosis 187:238–250CrossRefPubMed Shukla N, Maher J, Masters J, Angelini GD, Jeremy JY (2006) Does oxidative stress change ceruloplasmin from a protective to a vasculopathic risk factor? Atherosclerosis 187:238–250CrossRefPubMed
31.
go back to reference Wan S, Yim A, Shukla N et al (2007) Orally administered penicillamine is a potent inhibitor of neointimal and medial thickening in porcine saphenous vein grafts. J Thorac Cardiovasc Surg 133:494–500CrossRefPubMed Wan S, Yim A, Shukla N et al (2007) Orally administered penicillamine is a potent inhibitor of neointimal and medial thickening in porcine saphenous vein grafts. J Thorac Cardiovasc Surg 133:494–500CrossRefPubMed
32.
go back to reference West EJ, Guzik TJ, Black E et al (2000) Enhanced superoxide production in experimental venous bypass graft intimal hyperplasia. Arterioscler Thromb Vasc Biol 21:189–194 West EJ, Guzik TJ, Black E et al (2000) Enhanced superoxide production in experimental venous bypass graft intimal hyperplasia. Arterioscler Thromb Vasc Biol 21:189–194
33.
go back to reference West NE, Qian H, Guzik TJ et al (2001) Nitric oxide synthase (nNOS) gene transfer modifies venous bypass graft remodeling: effects on vascular smooth muscle cell differentiation and superoxide production. Circulation 104:1526–1532CrossRefPubMed West NE, Qian H, Guzik TJ et al (2001) Nitric oxide synthase (nNOS) gene transfer modifies venous bypass graft remodeling: effects on vascular smooth muscle cell differentiation and superoxide production. Circulation 104:1526–1532CrossRefPubMed
34.
go back to reference Guzik TJ, Mussa S, Gastaldi D et al (2002) Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105:1656–1662CrossRefPubMed Guzik TJ, Mussa S, Gastaldi D et al (2002) Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105:1656–1662CrossRefPubMed
35.
go back to reference Mangoni AA, SherWood RA, Asonganyi B, Swift CG, Thomas S, Jackson SH (2005) Short-term oral folic acid supplementation enhances endothelial function in patients with type 2 diabetes. Am J Hypertens 218:220–226CrossRef Mangoni AA, SherWood RA, Asonganyi B, Swift CG, Thomas S, Jackson SH (2005) Short-term oral folic acid supplementation enhances endothelial function in patients with type 2 diabetes. Am J Hypertens 218:220–226CrossRef
36.
go back to reference Title LM, Ur E, Giddens K, McQueen MJ, Nassar BA (2006) Folic acid improves endothelial dysfunction in type 2 diabetes—an effect independent of homocysteine-lowering. Vasc Med 11:101–109CrossRefPubMed Title LM, Ur E, Giddens K, McQueen MJ, Nassar BA (2006) Folic acid improves endothelial dysfunction in type 2 diabetes—an effect independent of homocysteine-lowering. Vasc Med 11:101–109CrossRefPubMed
37.
go back to reference van Etten RW, de Koning EJ, Verhaar MC et al (2002) Impaired NO-dependent vasodilation in patients with type II (non-insulin-dependent) diabetes mellitus is restored by acute administration of folate. Diabetologia 45:1004–1010CrossRefPubMed van Etten RW, de Koning EJ, Verhaar MC et al (2002) Impaired NO-dependent vasodilation in patients with type II (non-insulin-dependent) diabetes mellitus is restored by acute administration of folate. Diabetologia 45:1004–1010CrossRefPubMed
38.
go back to reference Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA (1997) Hyperhomocysteinaemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 95:1119–1121PubMed Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA (1997) Hyperhomocysteinaemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 95:1119–1121PubMed
39.
go back to reference Antoniades C, Shirodaria C, Warrick N et al (2006) 5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 114:1193–1120CrossRefPubMed Antoniades C, Shirodaria C, Warrick N et al (2006) 5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 114:1193–1120CrossRefPubMed
40.
go back to reference Van Hecke MV, Dekker JM, Nijpels G et al (2008) Homocysteine, S-adenosylmethionine and S-adenosylhomocysteine are associated with retinal microvascular abnormalities: the Hoorn Study. Clin Sci (Lond) 114:479–487CrossRef Van Hecke MV, Dekker JM, Nijpels G et al (2008) Homocysteine, S-adenosylmethionine and S-adenosylhomocysteine are associated with retinal microvascular abnormalities: the Hoorn Study. Clin Sci (Lond) 114:479–487CrossRef
41.
go back to reference Brazionis L, Rowley K Sr, Itsiopoulos C, Harper CA, O’Dea K (2008) Homocysteine and diabetic retinopathy. Diabetes Care 31:50–56CrossRefPubMed Brazionis L, Rowley K Sr, Itsiopoulos C, Harper CA, O’Dea K (2008) Homocysteine and diabetic retinopathy. Diabetes Care 31:50–56CrossRefPubMed
42.
go back to reference Martin A, Komada MR, Sane DC (2003) Abnormal angiogenesis in diabetes mellitus. Med Res Rev 23:117–145CrossRefPubMed Martin A, Komada MR, Sane DC (2003) Abnormal angiogenesis in diabetes mellitus. Med Res Rev 23:117–145CrossRefPubMed
43.
go back to reference Brem H, Canic T (2007) Cellular and molecular basis of wound healing in diabetes. J Clin Invest 117:1219–1222CrossRefPubMed Brem H, Canic T (2007) Cellular and molecular basis of wound healing in diabetes. J Clin Invest 117:1219–1222CrossRefPubMed
44.
go back to reference Lugue Contreras D, Vargas Robles H, Romo E, Rios A, Escalante B (2006) The role of nitric oxide in the post-ischemic revascularization process. Pharmacol Ther 112:553–563CrossRef Lugue Contreras D, Vargas Robles H, Romo E, Rios A, Escalante B (2006) The role of nitric oxide in the post-ischemic revascularization process. Pharmacol Ther 112:553–563CrossRef
Metadata
Title
Folic acid administration reduces neointimal thickening, augments neo-vasa vasorum formation and reduces oxidative stress in saphenous vein grafts from pigs used as a model of diabetes
Authors
J. Bloor
N. Shukla
F. C. T. Smith
G. D. Angelini
J. Y. Jeremy
Publication date
01-05-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 5/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1680-5

Other articles of this Issue 5/2010

Diabetologia 5/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.